Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.60 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11023644 | 0.90 | BCL9 (0.70) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL370103 | 0.89 | KMT2A (0.52) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL27730064 | 0.87 | KMT2A (0.57) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL31150525 | 0.86 | KMT2A (0.59) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL27546335 | 0.86 | KMT2A (0.59) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL16546594 | 0.86 | KMT2A (0.59) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL4246892 | 0.84 | KMT2A (0.63) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL6836918 | 0.84 | BCL9 (0.64) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL898796 | 0.82 | BCL9 (0.62) | BCL9CTNNB1KMT2AALDH1A1MAPT | |
| SCHEMBL2292825 | 0.82 | BCL9 (0.62) | BCL9CTNNB1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| CN-120081908-A | Multifunctional probe based on protein dynamic combination and preparation and application thereof | 莎穆(上海)生物科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-119490560-A | Tetrafunctional boron medicine compound, preparation method, application and pharmaceutical composition | 东莞市人民医院 | 2025-02-21 | — | — | CN | claimed |
| US-20240180856-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2024-06-06 | — | — | US | claimed |
| CN-117700479-A | Targeted prostate specific membrane antigen inhibitor, radioactive marker, preparation method and application thereof | 原子高科股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-20240053349-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2024-02-15 | — | — | US | claimed |
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | INDI MOLECULAR, INC. (US) | 2023-09-26 | — | — | US | claimed |
| US-11733246-B2 | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) | INDI MOLECULAR, INC. (US) | 2023-08-22 | — | — | US | claimed |
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | claimed |
| US-10004760-B2 | Microbubble complexes and methods of use | GENERAL ELECTRIC COMPANY (US) | 2018-06-26 | — | — | US | claimed |
| CN-107737335-A | Microvesicle compound and application method | 通用电气公司 | 2018-02-27 | — | — | CN | claimed |
| EP-2758081-B1 | MICROBUBBLE COMPLEXES AND METHODS OF USE | GEN ELECTRIC (US) | 2017-02-08 | — | — | EP | claimed |
| US-20170007636-A1 | MICROBUBBLE COMPLEXES AND METHODS OF USE | GENERAL ELECTRIC COMPANY | 2017-01-12 | — | — | US | claimed |
| EP-2758081-A1 | MICROBUBBLE COMPLEXES AND METHODS OF USE | General Electric Company (US) | 2014-07-30 | — | — | EP | claimed |
| CN-103957940-A | Microbubble complexes and methods of use | GEN ELECTRIC | 2014-07-30 | — | — | CN | claimed |
| WO-2013041500-A1 | MICROBUBBLE COMPLEXES AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-03-28 | — | — | WO | claimed |
| US-20130072854-A1 | MICROBUBBLE COMPLEXES AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-03-21 | — | — | US | claimed |
| CN-101380317-B | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD | 2010-12-08 | — | — | CN | claimed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | BCL9 2830/4885CTNNB1 3842/4885KMT2A 4334/4885 |
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | BCL9 1727/4885CTNNB1 3149/4885KMT2A 4195/4885 |
| US-20240053349-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | BCL9 1727/4885CTNNB1 3149/4885KMT2A 4195/4885 |
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | TP53, BAX, RNASE1 | BCL9 233/4885CTNNB1 3597/4885KMT2A 4697/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | BCL9 233/4885CTNNB1 3597/4885KMT2A 4697/4885 |
| US-20240180856-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | BCL9 233/4885CTNNB1 3597/4885KMT2A 4697/4885 |
| US-11733246-B2 | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | BCL9 1727/4885CTNNB1 3149/4885KMT2A 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.